These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 29331886)

  • 1. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
    BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Anticancer Activity of
    Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
    Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer.
    Kim J; Chang HS; Yun HJ; Chang HJ; Park KC
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.
    Park KC; Kim SM; Jeon JY; Kim BW; Kim HK; Chang HJ; Lee YS; Kim SY; Choi SH; Park CS; Chang HS
    Neoplasia; 2017 Mar; 19(3):145-153. PubMed ID: 28142087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Kobayashi Y; Van Bui D; Sawada S; Yun Y; Mitani A; Kondo N; Katano T; Tanigawa N; Akama T; Kanda A
    Exp Cell Res; 2021 Jan; 398(1):112390. PubMed ID: 33227314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
    Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
    Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.